Profile data is unavailable for this security.
About the company
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-91.00m
- Incorporated2020
- Employees74.00
- LocationDisc Medicine Inc321 Arsenal Street, Suite 101WATERTOWN 02472United StatesUSA
- Phone+1 (617) 674-9274
- Fax+1 (302) 655-5049
- Websitehttps://www.discmedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics Inc | 165.85m | -79.66m | 1.30bn | 593.00 | -- | 19.66 | -- | 7.81 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.36bn | 23.00 | -- | 6.33 | -- | 2,724.06 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Ardelyx Inc | 210.00m | -65.15m | 1.39bn | 267.00 | -- | 9.45 | -- | 6.61 | -0.2788 | -0.2788 | 0.9052 | 0.6244 | 0.7572 | 2.74 | 9.06 | 786,513.10 | -23.49 | -46.14 | -30.26 | -57.32 | 86.03 | 88.15 | -31.02 | -240.87 | 3.99 | -6.91 | 0.4055 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Disc Medicine Inc | 0.00 | -91.00m | 1.42bn | 74.00 | -- | 2.90 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -15.37m | 1.45bn | 29.00 | -- | 7.70 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Xencor Inc | 133.62m | -177.37m | 1.46bn | 280.00 | -- | 2.28 | -- | 10.90 | -2.90 | -2.90 | 2.19 | 9.14 | 0.1666 | -- | 6.35 | 477,207.20 | -22.40 | -3.70 | -24.25 | -4.12 | -- | -- | -134.45 | -15.92 | -- | -- | 0.0331 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Dynavax Technologies Corp | 249.70m | 17.18m | 1.47bn | 408.00 | 110.87 | 2.28 | 67.81 | 5.88 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Spyre Therapeutics Inc | 0.00 | -185.98m | 1.47bn | 50.00 | -- | 6.73 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -35.29m | 1.48bn | 20.00 | -- | 12.91 | -- | -- | -1.23 | -1.23 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -39.40 | -- | -39.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Arcus Biosciences Inc | 247.00m | -249.00m | 1.51bn | 577.00 | -- | 2.37 | -- | 6.10 | -3.10 | -3.10 | 3.02 | 6.96 | 0.2053 | -- | 7.06 | 428,076.30 | -20.70 | -15.85 | -24.57 | -18.25 | -- | -- | -100.81 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Syndax Pharmaceuticals Inc | 3.50m | -264.08m | 1.53bn | 112.00 | -- | 3.52 | -- | 437.64 | -3.38 | -3.38 | 0.0447 | 5.11 | 0.0077 | -- | 0.6132 | 31,250.00 | -58.15 | -27.90 | -63.20 | -30.15 | -- | -- | -7,545.20 | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| CareDx Inc | 297.08m | -159.64m | 1.54bn | 635.00 | -- | 5.82 | -- | 5.19 | -2.99 | -2.99 | 5.62 | 5.03 | 0.6053 | 5.46 | 5.04 | 467,848.80 | -32.53 | -17.54 | -38.52 | -20.85 | 64.98 | 65.50 | -53.73 | -27.78 | 3.85 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Kura Oncology Inc | 0.00 | -181.75m | 1.55bn | 142.00 | -- | 3.32 | -- | -- | -2.23 | -2.23 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -36.00 | -26.04 | -38.16 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0198 | -- | -- | -- | -12.36 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Disc Medicine Inc's reporting currency: US Dollar USD
37.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Paradigm BioCapital Advisors LPas of 30 Jun 2024 | 2.70m | 9.10% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 1.65m | 5.54% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.29m | 4.34% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 1.11m | 3.74% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.08m | 3.64% |
| Logos Global Management LPas of 30 Jun 2024 | 925.00k | 3.11% |
| Point72 Asset Management LPas of 30 Jun 2024 | 761.43k | 2.56% |
| Adage Capital Management LPas of 30 Jun 2024 | 618.50k | 2.08% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 592.80k | 1.99% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 553.44k | 1.86% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
